NEW YORK (GenomeWeb) – Paul Billings has joined Omicia as chief medical officer and will serve on the company's scientific advisory board. Billings was previously chief medical officer at Thermo Fisher's Life Technologies. Before that, he was founding and acting director and CSO at the Genomic Medicine Institute at El Camino Hospital. He was also previously president, CEO, and director of CELLective Dx, as well as senior vice president and senior geneticist at Laboratory Corporation of America. He is currently a director at Trovagene and CollabRx.
Qiagen said this week that Detlev Riesner, a Qiagen co-founder, retired earlier this month as chairman of the company's supervisory board after having served as a member of the board since 1996 and as chairman since 2003.
Werner Brandt has been selected to become the new chairman of the supervisory board. Brandt joined the board in 2007 and was appointed the same year as chairman of the audit committee. He is also retiring in 2014 as a member of the executive board of German software firm SAP.
All other members of Qiagen's supervisory board – Stéphane Bancel, Metin Colpan, Manfred Karobath, Lawrence Rosen and Elizabeth Tallett – are being proposed for re-election to one-year terms at the company's annual general meeting.
Qiagen also said that Elaine Mardis is being proposed for election as a new member of the supervisory board at the meeting. Mardis is co-director of The Genome Institute at Washington University in St. Louis. She is a professor of medicine and genetics with an adjunct appointment in molecular microbiology, and has served in various positions at Washington University School of Medicine; as a technical consultant for several commercial high-throughput sequencing laboratories; and as a member of the Ingenuity scientific advisory board. Mardis has previously served on a number of scientific advisory boards, including Pacific Biosciences, Orion Genomics, and DNAnexus. She is a former director of Celera, Applied Biosystems, and Applera.
DNA Electronics said this week that it has appointed Steve Allen as chief operating officer and doubled its development team from 30 to 60 scientists and engineers. Allen is a former board member and advisor to Solexa, now part of Illumina. Allen most recently served as managing director for LGC Forensics and has also worked for i2r Limited, Mettler Toledo, and PerkinElmer.
Allen's appointment and the expansion of the development team follow a recent investment in the company by the Genting Group, which DNAe will use to develop the Genalysis diagnostic product for point-of-care applications.
SISCAPA Assay Technologies has appointed Gustavo Salem president and CEO. Salem was previously an SAT board member. He also formerly was VP and general manager of the Biological Systems Division at Agilent, as well as president and CEO of Assay Designs.
Repligen Corporation said this week it has tapped former Life Technologies veteran Tony Hunt to be chief operating officer, a new position at the company. Hunt most recently was president of Life Technologies' BioProduction unit, and he formerly spent eight years at Applied Biosystems as product director of marketing. He began his career working in process development at Repligen.
Millennium Laboratories has added three new members to its management team: Nikhil Nayak, Steven Soe, and Michael Flowers.
Nayak, who formerly worked in sales and development at Forest Laboratories, will serve as chief marketing officer. So, who previously was VP of regulatory affairs at AssureRx Health, was named chief compliance officer. Flowers, who recently was VP of government accounts for the Walgreens drug store chain, has joined Millennium as VP of government operations.
The Broad Institute of MIT and Harvard have appointed two new members to its senior leadership team, including Samantha Singer as chief operating officer and Clare Midgley as chief communications officer.
Singer formerly was VP of corporate strategy and chief of staff for the CEO at Biogen Idec. As COO at Broad she will oversee the institute's human resources, finance, facilities, and IT teams, as well as the office of strategic alliances and partnering.
Midgley is a communications strategy consultant who formerly was VP of global corporate affairs at Millennium Pharmaceuticals
Global Genomics Group, a life sciences group combining phenotyping with pan-omics to identify novel biomarkers and drug targets, has appointed Harry Davis Jr. as chief drug development officer. He will be leading the drug discovery group together with Szilard Voros, co-founder and CEO of G3. Currently, Davis is CSO of CVPath Institute and was previously a distinguished research fellow in the cardiovascular/atherosclerosis research group at Merck Research Labs.
Alexander Kohlmann is now director of bioscience at AstraZeneca. Previously, he headed up the department of next-generation sequencing and microarrays at the Munich Leukemia Laboratory. Before that, he was research alliance manager at Roche Diagnostics.
Jamie Coffin has joined Terascala's board of directors. Prior to joining Terascala, Coffin was the president and general manager for Dell's Healthcare and Life Science division. Before he worked at Dell, Coffin was worldwide vice president of IBM Healthcare and Life Sciences.
Promoted? Changing jobs? GenomeWeb wants to know. [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.